Prescription drugs and pregnancy

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 6, 2003, Pages 949-961

  Webster, William S ^a   Freeman, Jane A D ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Birth defects; Drugs; Pregnancy; Prescribing

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ATENOLOL; BUSULFAN; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; CYTARABINE; DANAZOL; DIETHYLSTILBESTROL; ETRETIN; ETRETINATE; FLUCONAZOLE; IMIPRAMINE; ISOTRETINOIN; LITHIUM; METHOTREXATE; MISOPROSTOL; PENICILLAMINE; PHENOBARBITAL; PRIMIDONE; PROMETHAZINE; SIMVASTATIN; STREPTOMYCIN; TACROLIMUS; TERATOGENIC AGENT; THALIDOMIDE; TRIMETHADIONE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

BIRTH DEFECT; DOSE RESPONSE; DRUG SAFETY; EMBRYOTOXICITY; EPIDEMIOLOGICAL DATA; FEMALE; FETUS; FETUS MATURITY; FETUS RISK; FIRST TRIMESTER PREGNANCY; HUMAN; INFORMED CONSENT; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; PRESCRIPTION; QUANTITATIVE ANALYSIS; REVIEW; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; TERATOGENICITY; THIRD TRIMESTER PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; FEMALE; HUMANS; PHARMACEUTICAL PREPARATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; PRESCRIPTIONS, DRUG; RISK ASSESSMENT;

EID: 0038009061     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.6.949     Document Type: Review

References (100)

1. MACKLON NS, GERAEDTS JPM, FAUSER BCJM: Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. Human Reprod. Update (2002) 8:333-343.
2. BECKMAN DA, BRENT RL: Prenatal and perinatal biology and medicine (Volume 2). Kretchmer N, Quilligan EJ, Johnson JD, (Eds), Harwood Academic Publishers, Switzerland (1987):121-154.
3. WARKANY J: History of Teratology. In: Handbook of Teratology (Volume 1). Wilson JG, Clarke Fraser F (Eds), Plenum Press, New York, USA (1997):3-45.
4. WEBSTER WS, FREEMAN JAD: Is this drug safe in pregnancy? Reprod. Toxicol. (2001) 15:619-629.
5. BRENT RL: Bendectin: review of the medical literature of a comprehensively studied human nontratogen and the most prevalent tortogen-litigen. Reprod. Toxicol. (1995) 9:337-349.
6. HOLMES LB, HARVEY EA. COULL BA et al.: The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. (2001) 344:1132-1138.
7. BEGHI E, ANNEGERS JF: Pregnancy registries in epilepsy. The Collaborative Group for the Pregnancy Registries in Epilepsy. EpiLepsia (2001) 42:1422-1425.
8. BRIGGS GG, FREEMAN RK, YAFFE SJ: Drug in Pregnancy and Lactation. Lippincott Williams & Wilkins, Philadelphia, USA (2002).
9. OMTZIGT JG, LOS FJ, GROBBEE DE et al.: The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology (1992) 42(Suppl. 5):119-125.
10. SCOLNIK D, NULMAN I, ROVET J et al.: Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA (1994) 271:767-770.
11. MOORE SJ, TURNPENNY P, QUINN A et al.: A clinical study of 57 children with fetal anticonvulsant syndromes. J. Med. Genet. (2000) 37:489-497.
12. TENNIS P, ELDRIDGE RR: International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia (2002) 43:1161-1167.
13. EBERT U, LOFFLER H, KIRCH W: Cytotoxic therapy and pregnancy. Pharmacol. Ther. (1997) 74:207-220.
14. SCHARDEIN J: Chemically-induced birth defects, 3rd edn, Marcel Dekker, New York, USA (2002).
15. VAN DRIEL D, WESSELING J, SAUER PJJ, TOUWEN BCL, VAN DER VEER E, HEYMANS HSA: Teratogen update: fetal effects after in utero exposure to coumarins. Overview of cases, follow-up findings, and pathogenesis. Teratology (2002) 66:127-140.
16. LAMMER EL, HAYES AM, SCHUNIOR A, HOLMES LB: Unusually high risk for adverse outcomes of pregnancy following fetal isotretinoin exposure. Am. J. Hum. Genet. (1988) 43:A58.
17. ROSA FW, WILK AL, KELSEY FO: Ieratogen update: vitamin A congeners. Teratology (1986) 33:355-364.
18. ADAMS J, LAMMER EJ: Neurobehavioral teratology of isotretinoin Reprod. Toxicol. (1993) 7:175-177.
19. NEWMAN CGH: Teratogen update: clinical aspects of thalidomide embryopathy - a continuing preoccupation. Teratology (1985) 32:133-144.
20. ZALSTEIN E, XOREN G, EINARSON T, FREEDOM RM: A case-control study on the association between first trimester exposure to lithium and Ebstein's anomaly. Am. J. Cardiol. (1990) 65:817-818.
21. COHEN LS, FRIEDMAN JM, JEFFERSON JW, JOHNSON EM, WEINER ML: A re-evaluation of risk of in utero exposure to lithium. JAMA (1994) 271:146-150.
22. MOORE JA: An assessment of lithium using the IEHR evaluative process for assessing human developmental and reproductive toxicity of agents. IERR Expert Scientific Committee. Reprod. Toxicol. (1995) 9:175-210.
23. ROSA FW: Teratogen update: penicillamine. Teratology (1986) 33:127-131.
24. LEE BE, FEINBERG M, ABRAHAM JJ, MURTHY ARK: Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr. Infect. Dis. J. (1992) 11:1062-1064.
25. PURSLEY TJ, BLOMQUIST IK, ABRAHAM J, ANDERSEN HF, BARTLEY JA: Fluconazole-induced congenital anomalies in three infants. Clin. Infect. Dis. (1996) 22:336-340.
26. GONZALEZ CH, MARQUES-DIAS MJ, KIM CA et al.: Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet (1998) 351:1624-1627.
27. PASTUSZAK AL, SCHULER L, SPECK-MARTINS CE et al: Use of misoprostol during pregnancy and Mobius' syndrome in infants. N. Engl. J. Med. (1998) 338:1881-1885.
28. GRUMBACH MM, DUCHARME JR: The effects of androgens on fetal sexual development. Androgen-induced female pseudohermaphrodism. Fertil Steril. (1960) 11:157-180.
29. AARSKOG D: Clinical and cytogenic studies in hypospadias. Acta Paedritr. Scand. (1970) 203(Suppl. 203):7-62.
30. FLOYD RL, DECOUFLE P, HUNGERFORD DW: Alcohol use prior to pregnancy recognition. Am. J. Prev. Med. (1999) 17:101-107.
31. HONEIN MA. PAULOZZI LJ. ERICKSON JD: Continued occurrence of Accutane-exposed pregnancies. Teratology (2001) 64:142-147.
32. DOERING PL, BOOTHBY LA, CHEOK M: Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Am. J. Obstet. Gynecol. (2002) 187:333-339.
33. WHITE CS, MASON AC, FEEHAN M, TEMPLETON PA. Informed consent for percutaneous lung biopsy: comparison of two consent protocols based on patient recall after the procedure. Am. J. Roentgen. (1995) 165:1139-1142.
34. OLESEN C, SONDERGAARD C, THRANE N et al.: EuroMAP Group. Do pregnant women report use of dispensed medications? Epidemiol. 12:497-501.
35. WILLIAMS J, MYSON V, STEWARD S et al.: Self-discontinuation of antiepileptic medication in pregnancy: detection by hair analysis. Epilepsia (2002) 43:824-831.
36. Australian Drug Evaluation Committee, Prescribing medicines in pregnancy 4th edition, An Australian categorisation of risk of drug use in pregnancy, Canberra (1999) ISBN 0 642 41553 6.
37. LIFSHITZ M, GAVRILOV V, GALIL A, LANDAU D: A four year survey of neonatal withdrawal: evaluation and treatment. IMAJ (2001) 3:17-20.
38. SABATOWSKI R, RADBRUCH L, GROND S, GOHRING U-J: Treatment of low back pain with opioids during pregnancy in a patient with incomplete tetraplegia. Acta Anaesthesiol. Scand. (2000) 44:348-350.
39. OSTENSEN M: Non-steroidal anti-inflammatory drugs in pregnancy. Scand. J. Rheumatol. (1998) 27(Suppl. 107):128-132.
40. NORTON ME: Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology (1997) 56:282-292.
41. STIKA CS, GROSS GA, LEGUIZAMON G et al.: A prospective randomized safety trial of celocoxib for treatment of preterm labor. Am. J. Obstet. Gynecol. (2002) 187:653-660.
42. HERZ-PICCIOTTO I, HOPENHAYN-RICH C, GOLUB M et al.: The risks and benefits of taking aspirin during pregnancy. Epilipidiologic. Rev. (1990) 12:108-148.
43. KAAJA R. JULKUNEN H, VIINIKKA L et al.: Production of prostacyclin and thromboxane in lupus pregnancies. Effect of small doses of aspirin. Obstet. Gynecol. (1993) 82:327-331.
44. MOISE KJ JR: Polyhydramnios. Clin. Obstet. Gynecol. (1997) 40:266-279.
45. KOMHOFF M, WANG JL, CHENG HF et al.: Cyclooxygenase-2-sclective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int. (2000) 57:414-422.
46. VOYER LE, DRUT R. MENDEZ JH: Fetal renal maldevelopment with oligohydramnios following maternal use of piroxicam. Pediatr. Nephrol. (1994) 8:592-594.
47. VEERSEMA D, DE JONG PA, VAN WIJCK JA: Indomethacin and the fetal renal nonfunction syndrome. Eur. J. Obstet. Gynecol. Repro. Biol. (1983). 16:113-121.
48. NIELSEN GL, SORENSEN HT, LARSEN H, PEDERSEN L: Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Pediatrics (2001) 107:519-523.
49. CHAN LY, YUEN PM: Risk of miscarriage in pregnant users of NSAIDS. Br. Med. J. (2001) 322:1365.
50. JABLENSKY A. Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. Aust. NZ J. Psychiatry (2000) 34 (Suppl.):S26-S34.
51. AUERBACH JG, HANS SL, MARCUS J, MAEIR S: Maternal psychotropic medication and neonatal behavior. Neurotoxicol. Teratol. (1992) 14:399-406.
52. O'CONNOR M, JOHNSON GH, JAMES DI: Intrauterine effect of phenothiazines. Med. J. Aust. (1981) 1:416-417.
53. GOTLIB IA, WHIFFEN VE, MOUNT JH et al.: Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J. Consult. Clin. Psychol. (1989) 57:269-274.
54. MISRI S, SIVERTZ K: Tricyclic drugs in pregnancy and lactation: a preliminary report. Int. J. Psychiatr. Med. (1991) 21:157-171.
55. NORDENG H, LINDEMANN R, PERMINOV KV, REIKVAM A: Neonatal withdrawal symptoms after in utero exposure to selective serotonin reuptake inhibitors. Acta Pediatr. (2001) 90:288-291.
56. CHAMBERS CD, JOHNSON KA, DICK LM, FELIX RJ: Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. (1996) 335:1010-1015.
57. NARS PW, GIRARD J: Lithium carbonate intake during pregnancy leading to a large goitre in a premature infant. Am. J. Dis. Child. (1977) 131:924-925.
58. SCHOU M, AMDISEN A. JENSEN SE, OLSEN T: Occurrence of goitre during lithium treatment. Br. Med. J. (1968) 2:710-713.
59. BERGMAN U, ROSA FW, BAUM C, WIHOLM B-E, FAICH GA: Effects of exposure to benzodiazepines during fetal life. Lancet (1992) 340:694-696.
60. LAEGREID L, OLEGARD R, WALSTROM J, CONRADI N: Teratogenic effects of benzodiazepine use during pregnancy. J. Pediatr. (1989) 114:126-131.
61. REMENTERIA JL, BHATT K: Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J. Pediatr. (1977) 90:123-126.
62. NULMAN I, ROVET J, STEWART DE. et al.: Child Development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatr. (2002) 159:1889-1895.
63. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. American academy of pediatrics. Pediatr. (2000) 105:880-887.
64. SKJAERVEN R, WILCOX AJ, LIE RT: The interval between pregnancies and the risk of preeclampsia. N. Engl. J. Med. (2002) 346:33-38.
65. MAGEE LA, ORNSTEIN MP, VON DALDELSZEN P: Management of hypertension in pregnancy. Br. Med. J. (1999) 318:1332-1336.
66. SIBAI, BM: Treatment of hypertension in pregnant women. N. Engl. J. Med. (1996) 335:257-265.
67. MAGEE LA: Drugs in pregnancy. Antihypertensives. Best Practice Res. Clin. Obstet. Gynaecol. (2001) 15:827-845.
68. REY E, LELORIER J, BURGESS E, LANGE IR, LEDUC L: Report of the Canadian Hypertension Society Consensus Conference: 3 Pharmacologic treatment of hypertensive disorders in pregnancy. Can. Med. Assoc. J. (1997) 157:1245-1254.
69. RAMSAY LE, WILLLAMS B, JOHNSTON GD et al.: British Hypertension Society guidelines for hypertension management. Br. Med. J. (1999) 319:630-635.
70. WHITELAW A. Maternal methyldopa treatment and neonatal blood pressure. Br. Med. J. (1981) 283:1077-1079.
71. BRENT RL, BECKMAN D: Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counselors. teratology (1991) 43:543-546.
72. BARR M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology (1994) 50:399-409.
73. BUTTAR HS: An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development. Mol. Cell. Biochem (1997) 176:61-71.
74. REDMOND GP: Propanolol and fetal growth retardation. Semin. Perinatol. (1982) 6:142-147.
75. BUTTERS L, KENNEDY S, RUBIN PC: Atenolol in essential hypertension during pregnancy. Br. Med. J. (1990) 301:587-589.
76. LIP GYH, BEEVERS M, CHURCHILL D, SHAFFER LM, BEEVERS DG: Effect of atenolol on birth weight. Am. J. Cardiol. (1997) 79:1436-1438.
77. SIBAI BM, GONZALEZ AR, MABIE WC, MORETTI M: A comparison of labetalol plus hospitilization versus hospitilization alone in the management of preeclampsia remote from term. Obstet. Gynecol. (1987) 70:323-327.
78. WALTERS BN, REDMAN CW: Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine. Br. J. Obstet. Gynaecol. (1984) 91:330-336.
79. BEN-AMI M, GILADI Y, SHALEV E: The combination of magnesium sulfate and nifedipine: a cause of neuromuscular blockade. Br. J. Obstet. Gynaecol. (1994) 101:262-263.
80. SIBAI BM, GROSSMAN RA, GROSSMAN HG: Effects of diuretics on plasma volume in pregnancies with long term hypertension. Am. J. Obstet. Gynecol. (1984) 150:831-835.
81. MANSON JM, FREYSSINGES C, DUCROCQ MB, STEPHENSON WP: Postmarketing Surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod. Toxicol. (1996) 10:439-446.
82. MANDEL SJ, COOPER DS: The use of antithyroid drugs in pregnancy and lactation. J. Clin. Endocrinol. Metab. (2001) 86:2354-2359.
83. DIAV-CITRIN O, ORNOY A: Teratogen update: antithyroid drugs - methimazole, carbimazole and propylthiouracil. Teratology (2002) 65:38-44.
84. MORTIMER RH, CANNELL GR, ADDISON RS, JOHNSON LP, ROBERTS MS, BERNUS I: Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J. Clin. Endocrinol. Metab. (1997) 82:3099-3102.
85. HADDOW JE, PALOMAKI GE, ALLAN WC, WILLIAMS JR et al.: Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N. Engl. J. Med. (1999) 341:549-555.
86. CHERON RG, KAPLAN MM, LARSEN PR, SELENKOW HA, CRIGIER JF Jr. Neonatal thyroid function after propylthiouracil therapy for maternal Graves disease. N. Engl. J. Med. (1981) 304:525-528.
87. MILHAM S, ELLEDGE W. Maternal methimazole and congenital defects in children. Teratology (1972) 5:125-126.
88. MOMOTANI N, ITO K, HAMADA N, BAN Y, NISHIKAWA Y, MIMURA T: Maternal hyperthyroidism and congenital malformation in the offspring. Clin. Endocrinol. (1984) 20:695-700.
89. CLEMENTI M, DI GIANANTONIO E, PELO E, MAMMI I, BASILE RT, TENCONI R: Methimazole embryopathy: delineation of the phenotype. Am. J. Med. Genet. (1999) 83:43-46.
90. JOHNSSON E, LARSSON G, LJUNGGREN M: Severe malformation in infant born to hyperthyroid women on methimazole. Lancet (1997) 350:1520.
91. WILLIAMSON C: Gastrointestinal disease. Best practice Res. Clin. Obstet. Gynecol. (2001) 15:937-952.
92. FERRARA A, HEDDERSON MM, QUESENBERY CP, SELBY JV: Prevalence of gestational diabetes mellitus detected by the National Diabetes Data Group or the Carpenter and Coustan Plasma glucose thresholds. Diabetes (2002) 25:1625-1630.
93. KEMBALL ML, MCIVER C, MILNER RDG, NOURSE CH, SCHIFF D, TIERMAN JR: Neonatal hypoglycemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch. Dis. Child. (1970) 45:696-701.
94. PIACQUADIO K, HOLLINGSWORTH Dk, MURPHY H: Effects of in-utero exposure to oral hypoglycemic drugs. Lancet (1991) 338:866-869.
95. CHRISTENSEN HBT, MELANDER A: Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycemia. Eur. J. Endocrinol. (1998) 138:698-701.
96. LANGER O, CONWAY DL, BERKUS MD, XENAKIS EMJ, GONZALES O: A comparison of glyburide and insulin in women with gestational diabetes mellitus. N. Engl. J. Med. (2000) 343:1134-1138.
97. KAINZ A, IHOR H, COWBRICK I, GADGIL S, HAGIWARA D: Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplant (2000) 70:1718-1721.
98. COHLAN, SQ: Tetracycline-staining of teeth. Teratology (1977) 15:127-130.
99. CONWAY N, BIRT BD: Streptomycin in pregnancy: effect on the foetal ear. Br. Med. J. (1965) 2:260-263.
100. HUTCHIN T, HAWORTH I, HIGASHI K et al.: A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acid Res. (1993) 21:4174-4179.